Trials / Completed
CompletedNCT00141089
Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,026 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Tegaserod (HTF919) is an aminoguanidine indole compound and a member of a class of subgroup-selective 5-hydroxytryptamine (5-HT) agonists. The aim of this study was to evaluate the efficacy and safety of tegaserod on bowel habits in male patients with chronic constipation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tegaserod |
Timeline
- Start date
- 2004-03-01
- Completion
- 2005-02-01
- First posted
- 2005-09-01
- Last updated
- 2008-02-01
Source: ClinicalTrials.gov record NCT00141089. Inclusion in this directory is not an endorsement.